Tonix Pharmaceuticals Holding Co(TNXP)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

TNXP Tonix Pharmaceuticals Holding Co

盘前交易 05-14 08:08:18 EDT

13.84

+0.56

+4.22%

盘前13.70

-0.14-1.01%

07:18 EDT

最高13.86	最低13.02	成交量31.26万
今开13.26	昨收13.28	日振幅6.32%
总市值2.21亿	流通市值1.85亿	总股本1,594万
成交额426.16万	换手率2.33%	流通股本1,340万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"TNXP","market":"US","secType":"STK","nameCN":"Tonix Pharmaceuticals Holding Co","latestPrice":13.84,"timestamp":1778702400000,"preClose":13.28,"halted":0,"volume":312580,"hourTrading":{"tag":"盘前","latestPrice":13.7,"preClose":13.84,"latestTime":"07:18 EDT","volume":668,"amount":9169.700128,"timestamp":1778757483390,"change":-0.14,"changeRate":-0.010116,"amplitude":0.026734},"delay":0,"changeRate":0.04216867469879522,"floatShares":13400000,"shares":15940800,"eps":-14.095444,"marketStatus":"盘前交易","change":0.56,"latestTime":"05-14 08:08:18 EDT","open":13.26,"high":13.86,"low":13.0201,"amount":4261590.37542,"amplitude":0.063245,"askPrice":13.89,"askSize":164,"bidPrice":13.13,"bidSize":117,"shortable":3,"etf":0,"ttmEps":-14.095444,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1778765400000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":13.84,"preHourTrading":{"tag":"盘前","latestPrice":13.7,"preClose":13.84,"latestTime":"07:18 EDT","volume":668,"amount":9169.700128,"timestamp":1778757483390,"change":-0.14,"changeRate":-0.010116,"amplitude":0.026734},"postHourTrading":{"tag":"盘后","latestPrice":13.57,"preClose":13.84,"latestTime":"19:18 EDT","volume":2035,"amount":27789.5608,"timestamp":1778714308117,"change":-0.27,"changeRate":-0.019509,"amplitude":0.019509},"volumeRatio":0.6491769503648118,"impliedVol":0.5957,"impliedVolPercentile":0.0057},"requestUrl":"/m/hq/s/TNXP","defaultTab":"news","newsList":[{"id":"1135568762","title":"Tonix制药：预计年中启动Tonmya治疗重度抑郁症的二期临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1135568762","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135568762?lang=zh_cn&edition=full","pubTime":"2026-05-12 05:55","pubTimestamp":1778536517,"startTime":"0","endTime":"0","summary":"Tonix Pharmaceuticals Holding Co  宣布，预计将于今年年中启动其候选药物Tonmya用于治疗重度抑郁症的二期临床研究。重度抑郁症是一种常见且严重的精神健康障碍，对全球数百万人产生影响，目前仍存在大量未满足的临床需求。Tonmya作为一种新型潜在疗法，其二期研究旨在评估该药物对MDD患者的疗效与安全性。此次研究启动的预期，反映了Tonix Pharmaceuticals在推进其神经精神疾病治疗产品开发方面的持续努力。市场将密切关注该研究的后续进展及其可能带来的临床价值。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4583","TNXP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179080482","title":"Tonix制药Tonmya®获商业支付方覆盖 惠及约3500万美国患者","url":"https://stock-news.laohu8.com/highlight/detail?id=1179080482","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179080482?lang=zh_cn&edition=full","pubTime":"2026-05-06 19:04","pubTimestamp":1778065460,"startTime":"0","endTime":"0","summary":"Tonix Pharmaceuticals Holding Co（以下简称Tonix制药）宣布，其旗下药物Tonmya®已获得商业支付方承保，这将为美国约3500万名患者提供用药渠道。此次商业保险覆盖范围的突破，标志着该药物在可及性方面取得重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4583","BK4139","TNXP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103749805","title":"Tonix Pharmaceuticals公布TNX-4800莱姆病预防疫苗一期临床数据，并计划在2026年世界疫苗大会公布适应性二期实地研究方案","url":"https://stock-news.laohu8.com/highlight/detail?id=1103749805","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103749805?lang=zh_cn&edition=full","pubTime":"2026-03-31 19:02","pubTimestamp":1774954954,"startTime":"0","endTime":"0","summary":"Tonix Pharmaceuticals Holding Co（TNXP）宣布，将在2026年华盛顿世界疫苗大会上展示其候选疫苗TNX-4800用于预防莱姆病的一期临床试验数据。该公司同时披露了针对该疫苗的适应性二期实地研究规划，标志着其在莱姆病预防领域的战略布局取得重要进展。此次公布的数据将涵盖疫苗安全性、免疫原性等关键指标，而二期研究方案将采用适应性设计以优化临床试验效率。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4583","BK4139","TNXP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107348149","title":"Tonix制药启动TNX-1900一期药效学研究 首例受试者用药评估偏头痛及颅面疼痛治疗潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=1107348149","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107348149?lang=zh_cn&edition=full","pubTime":"2026-03-26 19:04","pubTimestamp":1774523046,"startTime":"0","endTime":"0","summary":"Tonix Pharmaceuticals Holding Corp.宣布，其研发的TNX-1900在一项由研究者发起的一期药效学研究中，已完成首例受试者给药。该研究旨在评估TNX-1900在治疗偏头痛及颅面疼痛方面的潜在疗效。TNX-1900作为一种鼻内给药的强化催产素制剂，其独特的作用机制可能为疼痛管理领域带来新的突破。若研究结果积极，TNX-1900有望为全球数百万受慢性疼痛困扰的患者提供创新治疗方案。公司表示将密切跟进研究进展，并及时向科学界与公众披露关键数据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TNXP","BK4583","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161672323","title":"Tonix Pharmaceuticals 获纳斯达克批准，将从纳斯达克资本市场转板至纳斯达克全球精选市场","url":"https://stock-news.laohu8.com/highlight/detail?id=1161672323","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1161672323?lang=zh_cn&edition=full","pubTime":"2026-03-03 19:11","pubTimestamp":1772536263,"startTime":"0","endTime":"0","summary":"Tonix Pharmaceuticals Holding Co (TNXP) 已正式获得纳斯达克交易所的批准，将其普通股的上市资格从纳斯达克资本市场转移至纳斯达克全球精选市场。\n此次转板标志着公司达到了更高的上市标准，通常意味着更强的财务表现和更严格的治理要求。这一变动预计将提升公司在全球投资者中的知名度和吸引力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4583","TNXP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189073772","title":"Tonix制药：Tonmya在三期RESILIENT研究中较安慰剂显著缓解纤维肌痛疼痛","url":"https://stock-news.laohu8.com/highlight/detail?id=1189073772","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189073772?lang=zh_cn&edition=full","pubTime":"2026-01-30 20:09","pubTimestamp":1769774948,"startTime":"0","endTime":"0","summary":"Tonix Pharmaceuticals Holding Corp.（TNXP）旗下药物Tonmya在关键性三期RESILIENT临床试验中取得突破性成果。研究数据显示，与安慰剂组相比，Tonmya治疗组在纤维肌痛患者疼痛症状改善方面表现出统计学意义的显著优势。\n该结果标志着纤维肌痛治疗领域的重要进展，为Tonix Pharmaceuticals后续向监管机构提交新药申请奠定了坚实基础。公司表示将继续推进相关数据分析工作，并积极筹备后续申报流程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TNXP","BK4583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119937454","title":"Tonix制药在2026年非阿片类疼痛治疗峰会上公布Tonmya™三期RESILIENT研究数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1119937454","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119937454?lang=zh_cn&edition=full","pubTime":"2026-01-30 20:04","pubTimestamp":1769774685,"startTime":"0","endTime":"0","summary":"Tonix Pharmaceuticals Holding Co（TNXP）在近日举办的2026年非阿片类疼痛治疗峰会上，正式公布了其创新药物Tonmya™（环苯扎林盐酸盐舌下片）的三期临床试验RESILIENT研究数据。该研究针对纤维肌痛症患者群体，结果显示Tonmya™在改善疼痛症状方面表现出显著疗效与良好安全性。此次数据发布进一步验证了舌下给药技术在非阿片类镇痛领域的应用潜力，为慢性疼痛治疗提供了新思路。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4583","TNXP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116595541","title":"Point72资产管理公司申报被动持股Tonix制药9.2%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=1116595541","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1116595541?lang=zh_cn&edition=full","pubTime":"2026-01-01 05:14","pubTimestamp":1767215655,"startTime":"0","endTime":"0","summary":"根据最新提交给美国证券交易委员会（SEC）的文件显示，截至12月29日，Point72资产管理公司已持有Tonix制药（Tonix Pharmaceuticals）9.2%的被动股权。这一持股比例表明，Point72对这家生物制药公司展现出了显著的投资兴趣。\n被动持股通常意味着投资机构不寻求对公司施加控制或影响，而是基于投资价值进行财务布局。Tonix制药作为一家专注于开发中枢神经系统疾病和治疗性疫苗的生物技术企业，此次获得知名对冲基金的持股，可能引发市场对其未来发展的关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4583","TNXP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127857749","title":"Tonix制药宣布2000万美元直接售股后股价上涨5.9%（更正：删除盘前交易相关表述）","url":"https://stock-news.laohu8.com/highlight/detail?id=1127857749","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1127857749?lang=zh_cn&edition=full","pubTime":"2025-12-29 22:52","pubTimestamp":1767019945,"startTime":"0","endTime":"0","summary":"Tonix Pharmaceuticals Holding Corp.（纳斯达克：TNXP）在宣布达成2000万美元的直接股票发行协议后，股价显著攀升5.9%。此次交易由机构投资者参与，公司将以每股特定价格直接发行普通股。\n消息公布后，市场反应积极，投资者信心得到提振。该笔资金将用于推进公司临床阶段项目的研发，包括针对中枢神经系统疾病和免疫学疗法的研究。公司管理层表示，此次融资将加强其资产负债表，并为关键管线的进展提供资金支持。\n（注：本报道已更正，移除了此前版本中关于盘前交易的不准确表述。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4583","TNXP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148125980","title":"Tonix制药公布针对莱姆病季节性预防的长效单抗Tnx-4800最新进展 已具备推进2/3期临床试验条件","url":"https://stock-news.laohu8.com/highlight/detail?id=1148125980","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148125980?lang=zh_cn&edition=full","pubTime":"2025-12-29 20:46","pubTimestamp":1767012400,"startTime":"0","endTime":"0","summary":"Tonix Pharmaceuticals Holding Corp.（简称Tonix制药）近日披露了其长效单克隆抗体Tnx-4800的研发计划更新。该抗体药物专为莱姆病的季节性预防而设计，目前已具备进入2/3期临床试验的成熟条件。\nTnx-4800作为一款创新疗法，旨在通过单次注射提供整个莱姆病高发季节的持续保护。此次进展标志着该药物在预防蜱媒传染病领域迈出关键一步。公司表示将基于现有数据与监管机构密切沟通，加快推进临床研究进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TNXP","BK4583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110103195","title":"Tonix Pharmaceuticals获得罗格斯大学授予的选择性Sigma-1受体拮抗剂Tnx-4900的许可，用于慢性神经性疼痛","url":"https://stock-news.laohu8.com/highlight/detail?id=1110103195","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110103195?lang=zh_cn&edition=full","pubTime":"2025-12-16 20:01","pubTimestamp":1765886474,"startTime":"0","endTime":"0","summary":"Tonix Pharmaceuticals获得罗格斯大学授予的选择性Sigma-1受体拮抗剂Tnx-4900的许可，用于慢性神经性疼痛","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TNXP","BK4583","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165886549","title":"Tonix Pharmaceuticals获得FDA批准开展Tnx-102 SLⅡ期研究以治疗重度抑郁症","url":"https://stock-news.laohu8.com/highlight/detail?id=1165886549","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165886549?lang=zh_cn&edition=full","pubTime":"2025-11-24 20:02","pubTimestamp":1763985760,"startTime":"0","endTime":"0","summary":"Tonix Pharmaceuticals获得FDA批准开展Tnx-102 SLⅡ期研究以治疗重度抑郁症","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TNXP","BK4583","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166751996","title":"Tonix Pharmaceuticals宣布Tonmya™（盐酸环托品舌下片）在美国商业上市，成为首个治疗纤维肌痛的创新药物","url":"https://stock-news.laohu8.com/highlight/detail?id=1166751996","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166751996?lang=zh_cn&edition=full","pubTime":"2025-11-17 20:01","pubTimestamp":1763380901,"startTime":"0","endTime":"0","summary":"Tonix Pharmaceuticals宣布Tonmya™（盐酸环托品舌下片）在美国商业上市，成为首个治疗纤维肌痛的创新药物。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TNXP","BK4583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512836904","title":"Tonix Pharmaceuticals Holding Corp.盘中异动 早盘股价大跌5.02%报10.40美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512836904","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512836904?lang=zh_cn&edition=full","pubTime":"2025-02-19 22:32","pubTimestamp":1739975548,"startTime":"0","endTime":"0","summary":"北京时间2025年02月19日22时32分，Tonix Pharmaceuticals Holding Corp.股票出现波动，股价大幅跳水5.02%。Tonix Pharmaceuticals Holding Corp.股票所在的生物技术行业中，整体涨幅为0.00%。Tonix Pharmaceuticals Holding Corp.公司简介：Tonix Pharmaceuticals Holding Corp 是一家生物制药公司，专注于开发、授权和商业化治疗人类疾病和缓解痛苦的治疗方法。Tonix还在罕见疾病和传染性疾病领域开发产品候选物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219223229abd4fe6b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219223229abd4fe6b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TNXP","BK4583","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512165045","title":"Tonix Pharmaceuticals Holding Corp.盘中异动 大幅下挫5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512165045","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512165045?lang=zh_cn&edition=full","pubTime":"2025-02-18 22:43","pubTimestamp":1739889789,"startTime":"0","endTime":"0","summary":"北京时间2025年02月18日22时43分，Tonix Pharmaceuticals Holding Corp.股票出现异动，股价快速下跌5.02%。Tonix Pharmaceuticals Holding Corp.股票所在的生物技术行业中，整体涨幅为0.60%。Tonix Pharmaceuticals Holding Corp.公司简介：Tonix Pharmaceuticals Holding Corp 是一家生物制药公司，专注于开发、授权和商业化治疗人类疾病和缓解痛苦的治疗方法。Tonix还在罕见疾病和传染性疾病领域开发产品候选物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218224309a24aaf63&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218224309a24aaf63&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TNXP","BK4583","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511524392","title":"Tonix Pharmaceuticals Holding Corp.盘中异动 早盘急速上涨5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2511524392","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511524392?lang=zh_cn&edition=full","pubTime":"2025-02-13 23:22","pubTimestamp":1739460145,"startTime":"0","endTime":"0","summary":"北京时间2025年02月13日23时22分，Tonix Pharmaceuticals Holding Corp.股票出现异动，股价大幅上涨5.04%。Tonix Pharmaceuticals Holding Corp.股票所在的生物技术行业中，整体涨幅为0.21%。Tonix Pharmaceuticals Holding Corp.公司简介：Tonix Pharmaceuticals Holding Corp 是一家生物制药公司，专注于开发、授权和商业化治疗人类疾病和缓解痛苦的治疗方法。Tonix还在罕见疾病和传染性疾病领域开发产品候选物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250213232226a244b66b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250213232226a244b66b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4583","TNXP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510387287","title":"Tonix Pharmaceuticals Holding Corp.盘中异动 大幅跳水5.11%报11.33美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2510387287","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510387287?lang=zh_cn&edition=full","pubTime":"2025-02-11 22:33","pubTimestamp":1739284405,"startTime":"0","endTime":"0","summary":"北京时间2025年02月11日22时33分，Tonix Pharmaceuticals Holding Corp.股票出现异动，股价快速下跌5.11%。Tonix Pharmaceuticals Holding Corp.股票所在的生物技术行业中，整体跌幅为0.95%。Tonix Pharmaceuticals Holding Corp.公司简介：Tonix Pharmaceuticals Holding Corp 是一家生物制药公司，专注于开发、授权和商业化治疗人类疾病和缓解痛苦的治疗方法。Tonix还在罕见疾病和传染性疾病领域开发产品候选物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502112233259881bd37&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502112233259881bd37&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4583","TNXP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510286501","title":"Tonix Pharmaceuticals Holding Corp.盘中异动 早盘大幅下挫5.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2510286501","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510286501?lang=zh_cn&edition=full","pubTime":"2025-02-10 22:47","pubTimestamp":1739198878,"startTime":"0","endTime":"0","summary":"北京时间2025年02月10日22时47分，Tonix Pharmaceuticals Holding Corp.股票出现异动，股价急速下挫5.17%。Tonix Pharmaceuticals Holding Corp.股票所在的生物技术行业中，整体涨幅为0.35%。Tonix Pharmaceuticals Holding Corp.公司简介：Tonix Pharmaceuticals Holding Corp 是一家生物制药公司，专注于开发、授权和商业化治疗人类疾病和缓解痛苦的治疗方法。Tonix还在罕见疾病和传染性疾病领域开发产品候选物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210224758a240a62e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210224758a240a62e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","TNXP","BK4583"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2509041277","title":"Tonix Pharmaceuticals Holding Corp.盘中异动 大幅下跌6.79%报13.96美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509041277","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509041277?lang=zh_cn&edition=full","pubTime":"2025-02-06 22:35","pubTimestamp":1738852550,"startTime":"0","endTime":"0","summary":"北京时间2025年02月06日22时35分，Tonix Pharmaceuticals Holding Corp.股票出现波动，股价快速下挫6.79%。Tonix Pharmaceuticals Holding Corp.股票所在的生物技术行业中，整体跌幅为0.19%。Tonix Pharmaceuticals Holding Corp.公司简介：Tonix Pharmaceuticals Holding Corp 是一家生物制药公司，专注于开发、授权和商业化治疗人类疾病和缓解痛苦的治疗方法。Tonix还在罕见疾病和传染性疾病领域开发产品候选物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206223550abc4d5c3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206223550abc4d5c3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4583","TNXP","BK4139"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2508577924","title":"Tonix Pharmaceuticals Holding Corp.盘中异动 早盘股价大跌15.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=2508577924","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2508577924?lang=zh_cn&edition=full","pubTime":"2025-02-04 22:31","pubTimestamp":1738679508,"startTime":"0","endTime":"0","summary":"北京时间2025年02月04日22时31分，Tonix Pharmaceuticals Holding Corp.股票出现异动，股价大幅下挫15.85%。Tonix Pharmaceuticals Holding Corp.股票所在的生物技术行业中，整体跌幅为0.58%。Tonix Pharmaceuticals Holding Corp.公司简介：Tonix Pharmaceuticals Holding Corp 是一家生物制药公司，专注于开发、授权和商业化治疗人类疾病和缓解痛苦的治疗方法。Tonix还在罕见疾病和传染性疾病领域开发产品候选物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250204223148a23928bf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250204223148a23928bf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","TNXP","BK4583"],"isVideo":false,"video":null,"gpt_icon":1}],"profile":{"websiteUrl":"http://www.tonixpharma.com","stockEarnings":[{"period":"1week","weight":-0.0579},{"period":"1month","weight":0.0663},{"period":"3month","weight":-0.0834},{"period":"6month","weight":-0.1296},{"period":"1year","weight":-0.3142},{"period":"ytd","weight":-0.114}],"compareEarnings":[{"period":"1week","weight":0.0116},{"period":"1month","weight":0.0819},{"period":"3month","weight":0.0896},{"period":"6month","weight":0.1047},{"period":"1year","weight":0.2649},{"period":"ytd","weight":0.0886}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Tonix Pharmaceuticals Holding Corp.2007年11月16日在内华达州成立。该公司是一家临床阶段的生物制药公司，专注于开发治疗和预防人类疾病和减轻痛苦的疗法和疫苗。该公司拥有大量正在开发的产品，这些产品是通过内部发现、许可、收购以及与学术机构和合同研究组织的合作来策划的。公司继续在合成生物学、精准医学、蛋白质工程、药物化学、分子生物学、药物基因组学和临床规模制造方面建设能力。该公司正在开发的疗法包括小分子和生物制剂。","yearOnYearQuotes":[{"month":1,"riseRate":0.692308,"avgChangeRate":0.190798},{"month":2,"riseRate":0.153846,"avgChangeRate":-0.161688},{"month":3,"riseRate":0.384615,"avgChangeRate":0.034254},{"month":4,"riseRate":0.230769,"avgChangeRate":-0.072453},{"month":5,"riseRate":0.461538,"avgChangeRate":0.021302},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.071625},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.11658},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.140207},{"month":9,"riseRate":0.153846,"avgChangeRate":-0.25769},{"month":10,"riseRate":0.384615,"avgChangeRate":-0.06224},{"month":11,"riseRate":0.384615,"avgChangeRate":-0.060378},{"month":12,"riseRate":0.538462,"avgChangeRate":0.052728}],"exchange":"NASDAQ","name":"Tonix Pharmaceuticals Holding Co","nameEN":"Tonix Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Tonix Pharmaceuticals Holding Co(TNXP)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Tonix Pharmaceuticals Holding Co(TNXP)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Tonix Pharmaceuticals Holding Co,TNXP,Tonix Pharmaceuticals Holding Co股票,Tonix Pharmaceuticals Holding Co股票老虎,Tonix Pharmaceuticals Holding Co股票老虎国际,Tonix Pharmaceuticals Holding Co行情,Tonix Pharmaceuticals Holding Co股票行情,Tonix Pharmaceuticals Holding Co股价,Tonix Pharmaceuticals Holding Co股市,Tonix Pharmaceuticals Holding Co股票价格,Tonix Pharmaceuticals Holding Co股票交易,Tonix Pharmaceuticals Holding Co股票购买,Tonix Pharmaceuticals Holding Co股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Tonix Pharmaceuticals Holding Co(TNXP)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Tonix Pharmaceuticals Holding Co(TNXP)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}